Abstract
Background Hemorrhoidectomy is still considered the mainstay of treatment for advanced and/or complicated hemorrhoids, although post-hemorrhoidectomy pain remains a challenging problem.
Objectives This study aimed to comparison the effect of intradermal methylene blue with adrenaline and Marcaine with adrenaline injection in pain relief after hemorrhoidectomy.
Matherial and methods In this single-center prospective double-blind randomized trial, Patients aged 18-60 years with the diagnosis of hemorrhoids with grade three or four candidate for open hemorrhoidectomy were enrolled. Patients were randomly divided into two groups. Intradermal injection during hemorrhoidectomy of 4 ml 1% methylene blue with adrenaline and 16 ml 0.5% Marcaine for patients in methylene blue group and 16 ml 0.5% Marcaine with adrenaline and 4 ml saline without methylene blue in control group was used. Patients’ information were recorded prospectively.
Results Ninety seven patients were enrolled. Postoperative pain in patients in methylene group between the 1st and 7th days after surgery was significantly lower than patients in control group. However, no significant difference was detected in pain scores between the two groups from 8th to the 14th days after surgery. Also, patients in methylene blue group received analgesic drugs were significantly less than control group between days 1 and 7 after the surgery.
Conclusion An intradermal application of 1 % methylene blue with adrenaline solution is associated with a positive effect on pain relief with low side effects related to sensory cutaneous innervation in all patients. It can achieve a long-acting analgesic effect with few complications.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
IRCT20190325043107N27
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the research ethics committee of Tabriz University of Medical Sciences and registered in the Iranian Registry of clinical trials with registration number IRCT20190325043107N27 (the full trial protocol can be accessed at: http://www.irct.ir).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors declare that they have no conflict of interest.
Data Availability
All data produced in the present work are contained in the manuscript